Neuromyotonia

Jump to: navigation, search

WikiDoc Resources for Neuromyotonia

Articles

Most recent articles on Neuromyotonia

Most cited articles on Neuromyotonia

Review articles on Neuromyotonia

Articles on Neuromyotonia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Neuromyotonia

Images of Neuromyotonia

Photos of Neuromyotonia

Podcasts & MP3s on Neuromyotonia

Videos on Neuromyotonia

Evidence Based Medicine

Cochrane Collaboration on Neuromyotonia

Bandolier on Neuromyotonia

TRIP on Neuromyotonia

Clinical Trials

Ongoing Trials on Neuromyotonia at Clinical Trials.gov

Trial results on Neuromyotonia

Clinical Trials on Neuromyotonia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Neuromyotonia

NICE Guidance on Neuromyotonia

NHS PRODIGY Guidance

FDA on Neuromyotonia

CDC on Neuromyotonia

Books

Books on Neuromyotonia

News

Neuromyotonia in the news

Be alerted to news on Neuromyotonia

News trends on Neuromyotonia

Commentary

Blogs on Neuromyotonia

Definitions

Definitions of Neuromyotonia

Patient Resources / Community

Patient resources on Neuromyotonia

Discussion groups on Neuromyotonia

Patient Handouts on Neuromyotonia

Directions to Hospitals Treating Neuromyotonia

Risk calculators and risk factors for Neuromyotonia

Healthcare Provider Resources

Symptoms of Neuromyotonia

Causes & Risk Factors for Neuromyotonia

Diagnostic studies for Neuromyotonia

Treatment of Neuromyotonia

Continuing Medical Education (CME)

CME Programs on Neuromyotonia

International

Neuromyotonia en Espanol

Neuromyotonia en Francais

Business

Neuromyotonia in the Marketplace

Patents on Neuromyotonia

Experimental / Informatics

List of terms related to Neuromyotonia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and Keywords:

Overview

Neuromyotonia, also known as Isaacs' Syndrome, is spontaneous muscular activity resulting from repetitive motor unit action potentials of peripheral origin.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

It develops as a result of both acquired or hereditary diseases. Acquired form is more frequent and is usually caused by antibodies against neuromuscular junction.

Autoreactive antibodies can be detected in a variety of peripheral (e.g. myasthenia gravis, Lambert-Eaton myasthenic syndrome) and central nervous system (e.g. paraneoplastic cerebellar degeneration, paraneoplastic limbic encephalitis) disorders. Their causative role has been established in some of these diseases but not all. Neuromyotonia is considered to be one of these with accumulating evidence for autoimmune origin over the last few years. Some neuromyotonia cases do not only improve after plasma exchange but they may also have antibodies in their serum samples against voltage-gated potassium channels.[1] Moreover, these antibodies have been demonstrated to reduce potassium channel function in neuronal cell lines.

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

As a result of muscular hyperactivity patients may present with muscle cramps, myotonia-like symptoms, excessive sweating, myokymia and fasciculations. A very small proportion of cases with neuromyotonia may develop central nervous system findings in their clinical course, causing a disorder called Morvan's syndrome and they may also have antibodies against potassium channels in their serum samples. Sleep disorder is only one of a variety of clinical conditions observed in Morvan's syndrome cases ranging from confusion and memory loss to hallucinations and delusions.

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

There is no known cure for neuromyotonia. The long-term prognosis for individuals with the disorder is uncertain. Anticonvulsants, including phenytoin and carbamazepine, usually provide significant relief from the stiffness, muscle spasms, and pain associated with neuromyotonia. Plasma exchange may provide short-term relief for patients with some forms of the acquired disorder.

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

  1. Maddison P (2006). "Neuromyotonia". Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 117 (10): 2118–27. doi:10.1016/j.clinph.2006.03.008. PMID 16843723.

Linked-in.jpg